Free Trial
NYSEAMERICAN:SYN

Synthetic Biologics (SYN) Stock Price, News & Analysis

Synthetic Biologics logo

About Synthetic Biologics Stock (NYSEAMERICAN:SYN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
57,700 shs
Average Volume
197,338 shs
Market Capitalization
$16.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYN Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

SYN Stock Analysis - Frequently Asked Questions

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) released its earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10.

Synthetic Biologics shares reverse split on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Meta Platforms (META).

Company Calendar

Last Earnings
11/02/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:SYN
CIK
894158
Employees
16
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.27 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.14%
Return on Assets
-22.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.14
Quick Ratio
4.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.95 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
15,844,000
Free Float
15,503,000
Market Cap
$16.16 million
Optionable
Not Optionable
Beta
1.38
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NYSEAMERICAN:SYN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners